The deal, which is due to be signed into law by President Trump, includes the biggest increase in FDA funding in several years.

Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.

Glenmark is rolling all of the new molecular entities in its pipeline into a separate U.S. company in an effort to speed the programs to market.

Passage Bio reeled in $115.5 million, which will support the development of five programs aimed at treating rare monogenic central nervous system diseases.

University of Geneva scientists showed how pancreatic cells that normally don't produce insulin can be converted to produce the hormone.

In our EuroBiotech roundup this week, DBV shares resubmission timeline, British Library pens deal to add lab capacity and ADC starts Imfinzi trial.

In this week's EuroBiotech Report, AstraZeneca clears out cancer projects, uniQure's hemophilia B drug clears test and Grey Wolf raises £10 million.

Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.

The funding will advance Vor's lead asset, an engineered hematopoietic stem cell therapy for acute myeloid leukemia.